Pedia Pain Focus

pain is the most common and devastating symptom of Sickle Cell Disease. Despite the slow and elusive developement of therapeutic intervention in Sickle cell disease that would halt the vasocclusive crisis and the related pain, last few decades have brought about good progress with successful hemopoetic stem cell transplant as well as several therapeutic agents targeting various aspect of teh pathophysiliogy of SCD.   In this episode, I review the 4 major targets in the pathophysiology of SCD and approved therapeutic interventions and agents as well as those that are further along clinical trial with very promising results.   Takeaways in This Episode What prompted me to do this update How this episode is different from and how it complements the earlier published episode about sickle cell disease The challenges presented by sickle cell disease The major presentation and impact of sickle cell disease 4 main therapeutic targets with advances and ongoing trials Newer FDA approved agents in management of vasoccl